WFRF:(Bernfort Lars)
Search: WFRF:(Bernfort Lars) > Implementation of E...
- 7 of 96
- Previous record
- Next record
- To hitlist
Implementation of Empagliflozin in Patients with Diabetes Mellitus Type 2 and Established Cardiovascular Disease : Estimation of 5-Year Survival and Costs in Sweden
-
- Bernfort, Lars (author)
- Linköpings universitet,Avdelningen för samhälle och hälsa,Medicinska fakulteten
-
- Husberg, Magnus (author)
- Linköpings universitet,Avdelningen för samhälle och hälsa,Medicinska fakulteten
-
- Wiréhn, Ann-Britt (author)
- Linköpings universitet,Avdelningen för samhälle och hälsa,Medicinska fakulteten,Region Östergötland, Forskningsstrategiska enheten
- show more...
- show less...
- (creator_code:org_t)
- 2020-10-06
- 2020
- English.
- In: Diabetes Therapy. - : Springer Berlin/Heidelberg. - 1869-6953 .- 1869-6961. ; 11, s. 2921-2930
- Journal article (peer-reviewed)
Abstract
Subject headings
Close
- IntroductionCardiovascular disease (CVD) affects approximately 30% of patients with diabetes mellitus type 2 (T2D) and leads to increased morbidity, decreased survival and increased healthcare utilization. The aim of this study was to estimate the impact of treating these patients with the sodium–glucose cotransporter 2 (SGLT2) inhibitor empagliflozin on survival and healthcare utilization.MethodsActual survival and healthcare utilization data from a 5-year retrospective cohort study on patients with T2D and CVD in the Region of Östergötland, Sweden were used as a starting point. Actual data were adjusted in accordance with risk reductions for mortality and CV events related to empagliflozin treatment as reported in the EMPA-REG OUTCOME study.ResultsApplying the risk reductions related to empagliflozin treatment on the cohort of patients with T2D and CVD in Östergötland resulted in an increase in 5-year survival of 96 days per patient and reduced costs for healthcare and drugs other than empagliflozin. Including the cost of empagliflozin, treatment led to an increased net cost per patient of approximately SEK 18,000 over 5 years.ConclusionEmpagliflozin treatment would reduce mortality and healthcare utilization in the patient group. The treatment strategy should be considered cost-effective, supporting a broad implementation of empagliflozin for patients with T2D and established CVD, in line with current national and international guidelines.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Endokrinologi och diabetes (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Endocrinology and Diabetes (hsv//eng)
Keyword
- Cardiovascular disease; Disease burden; Healthcare costs; Mortality; Pharmaceutical treatment; Register study; SGLT2 inhibitors; Type 2 diabetes
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
- Diabetes Therapy (Search for host publication in LIBRIS)
To the university's database
- 7 of 96
- Previous record
- Next record
- To hitlist
Find more in SwePub
- By the author/editor
- Bernfort, Lars
- Husberg, Magnus
- Wiréhn, Ann-Brit ...
- Rosenqvist, Ulf
- Gustavsson, Staf ...
- Karlsdotter, Kri ...
- show more...
- Levin, Lars-Åke
- show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
- MEDICAL AND HEAL ...
- and Clinical Medicin ...
- and Endocrinology an ...
- Articles in the publication
- Diabetes Therapy
- By the university
- Linköping University
Search outside SwePub
- Extend your search to:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - National Library Systems
- LIBRIS.kb.se
